Search results
Results from the WOW.Com Content Network
Antiplatelet therapy with one or more of these drugs decreases the ability of blood clots to form by interfering with the platelet activation process in primary hemostasis. Antiplatelet drugs can reversibly or irreversibly inhibit the process involved in platelet activation resulting in decreased tendency of platelets to adhere to one another ...
Generally, drugs outlined within the ATC code B01AC should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Antiplatelet drugs .
The second generation thienopyridine P2Y 12 receptor blocker clopidogrel is an effective antiplatelet agent useful for treatment of ischemic cerebrovascular, cardiac and peripheral arterial release. [27] Like other thienopyridine drugs, the drug was often combined with aspirin in clinical use. [23]
In medicine, glycoprotein IIb/IIIa inhibitors, also GpIIb/IIIa inhibitors, is a class of antiplatelet agents. Several GpIIb/IIIa inhibitors exist: abciximab (abcixifiban) (ReoPro) eptifibatide (Integrilin) tirofiban (Aggrastat) roxifiban; orbofiban
Generally, drugs outlined within the ATC code B01 should be included in this category. Please see WP:PHARM:CAT for more information. The main article for this category is Antithrombotic agents .
ATC code B01 Antithrombotic agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup B01 is part of the anatomical group B Blood and blood forming ...
The following are medications commonly prescribed cardiac pharmaceutical agents. The specificity of the following medications is highly variable, and often are not particularly specific to a given class. As such, they are listed as are commonly accepted.
Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus formation within the coronary artery.